The peripheral benzodiazepine receptor ligand PK11195 overcomes different resistance mechanisms to sensitize AML cells to gemtuzumab ozogamicin.
D000208:Acute Disease; D000617:Aminoglycosides / Q000494:pharmacology*; D000818:Animals; D000911:Antibodies, Monoclonal / Q000494:pharmacology*; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000494:pharmacology*; D016572:Cyclosporine / Q000494:pharmacology; D019008:Drug Resistance, Neoplasm; D000079982:Gemtuzumab; D015973:Gene Expression Regulation, Leukemic / Q000187:drug effects; D018922:HL-60 Cells; D006801:Humans; D007166:Immunosuppressive Agents / Q000494:pharmacology; D007546:Isoquinolines / Q000494:pharmacology*; D007951:Leukemia, Myeloid / Q000188:drug therapy* / Q000378:metabolism; D020024:Leukotriene Antagonists / Q000494:pharmacology; D008024:Ligands; D051379:Mice; D016688:Mice, Inbred NOD; D016513:Mice, SCID; D011422:Propionates / Q000494:pharmacology; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000235:genetics; D011804:Quinolines / Q000494:pharmacology; D011963:Receptors, GABA-A / Q000378:metabolism*; D023041:Xenograft Model Antitumor Assays; D051020:bcl-X Protein
D000617:Aminoglycosides; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; C494811:BCL2L1 protein, human; C494812:Bcl2l1 protein, mouse; D007166:Immunosuppressive Agents; D007546:Isoquinolines; D020024:Leukotriene Antagonists; D008024:Ligands; D011422:Propionates; D019253:Proto-Oncogene Proteins c-bcl-2; D011804:Quinolines; D011963:Receptors, GABA-A; D051020:bcl-X Protein; C059141:verlukast; D016572:Cyclosporine; D000079982:Gemtuzumab; C037850:PK 11195